the

initiative

ReLeef

Home  |  Contact Us

A Non-Profit Health Science Organization

 

The Releef Initiative is a non-profit pharmaceutical corporation. The basic approach of the organization is to operate as a “concept generator”, to develop new applications of old technology and leverage know-how and intellectual property in collaborations with for-profit companies. The organization is managed as a global network with representatives in US, Sweden and Russia. The corporate headquarter is in San Diego, California.

 

The Way We Work

 

The corporation operates as a virtual R&D organization, i.e. all research and development will be conducted by outsourcing. By working in this mode, Releef avoids time- and cash-consuming build-up and maintenance of internal infrastructure. The principal approach will involve development of new formulations and dosage forms of drugs that already have documented safety as well as re-positioning of old drugs, i.e. identify new disease areas for off-patent drugs that already have been extensively used.

Our Team

 

The organization has three principal constituents: its board of directors, it’s program management office, and the executive advisors. The Program Management Office (PMO) is ultimately responsible for the execution of operations and is maintained within The Releef Initiative. The project management approach employed by Releef is a stage-gated methodology streamlined to include five project management stages (phases) each ending with a specific decision point (gate).

Home           About Us            Our programs            News            How to Participate            Contact Us

About Us

Misha Denissenko

Director & Treasurer

Releef’s Treasurer has vast experience as a senior manager in drug discovery and diagnostics. At BD Biosciences, he led a R&D group involved in the development and production of commercial bioreagents. At Sequenom he was part of the drug discovery management team. Dr. Denissenko is the author of over 40 peer-reviewed publications and several book chapters on cancer.

 

 

 

 

Jonas Ekblom

Director & Officer

 

Dr. Ekblom currently serves as the CEO of BOWS Pharmaceuticals AG, a Swiss pharmaceutical group. He has held senior management positions in Pharmacia, Sequenom, Invitrogen and Nanostream and has been the founder of several biotech start-ups in drug discovery and diagnostics. Dr. Ekblom has experience of portfolio management in several therapeutic areas. He has published more than 50 articles on pharmacology and pharmacogenetics.

 

 

 

 

 

Johan Kördel

Director & Officer

Dr. Kördel has a solid academic training at University of Lund, Scripps and Harvard. He has held several executive management positions in Pharmacia and as a founder of Biovitrum where he served as SVP of Business Development. He now works as an independent Business Developement Consultant and is a member of the boards of three Biotech Companies: Respiratorius, Index Pharmaceuticals and iNovacia.